Eculizumab
- Generic Name
- Eculizumab
- Brand Names
- Soliris, Epysqli, Bekemv
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 219685-50-4
- Unique Ingredient Identifier
- A3ULP0F556
- Background
Eculizumab is a monoclonal antibody that targets complement protein C5. Binding to this protein prevents the activation of a complement terminal complex, which is used to treat a number of autoimmune conditions.
...
- Indication
Eculizumab is indicated in the US to treat paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis, atypical hemolytic uremic syndrome to inhibit complement-mediated thrombotic microangiopathy, and neuromyelitis optica spectrum disorder (NMOSD). It is also indicated in EU to treat PNH in both adult and pediatric patients.
- Associated Conditions
- Generalized Myasthenia Gravis, Neuromyelitis Optica Spectrum Disorders, Paroxysmal Nocturnal Haemoglobinuria (PNH), Thrombotic Microangiopathies
- Associated Therapies
- -
Eculizumab in Shiga-toxin Related Hemolytic and Uremic Syndrome Pediatric Patients - ECULISHU
- Conditions
- Interventions
- First Posted Date
- 2014-07-31
- Last Posted Date
- 2019-07-12
- Lead Sponsor
- University Hospital, Toulouse
- Target Recruit Count
- 100
- Registration Number
- NCT02205541
- Locations
- 🇫🇷
Clocheville Hospital, Tours, France
🇫🇷Pellegrin Hospital, Bordeaux, France
🇫🇷Trousseau Hospital, Paris, France
Prevention of Delayed Graft Function Using Eculizumab Therapy (PROTECT Study)
- First Posted Date
- 2014-05-22
- Last Posted Date
- 2018-12-17
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 288
- Registration Number
- NCT02145182
- Locations
- 🇧🇷
Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil
Eculizumab Therapy for Subclinical Antibody-mediated Rejection in Kidney Transplantation
- Conditions
- Interventions
- First Posted Date
- 2014-04-15
- Last Posted Date
- 2015-02-25
- Lead Sponsor
- Assistance Publique - Hôpitaux de Paris
- Registration Number
- NCT02113891
Eculizumab in Primary MPGN
- First Posted Date
- 2014-03-21
- Last Posted Date
- 2018-01-17
- Target Recruit Count
- 10
- Registration Number
- NCT02093533
- Locations
- 🇮🇹
Policlinico "Federico II" - U.O. Nefrologia, Napoli, Italy
🇮🇹Ospedale degli Infermi - U.O. Nefrologia e Dialisi, Rimini, Italy
🇮🇹C.I. Columbus-Università Cattolica del S.Cuore - UOC Nefrologia e Dialisi, Roma, Italy
Inhibition of Complement Activation (Eculizumab) in Guillain-Barre Syndrome Study
- First Posted Date
- 2014-01-07
- Last Posted Date
- 2014-09-23
- Lead Sponsor
- NHS Greater Glasgow and Clyde
- Target Recruit Count
- 30
- Registration Number
- NCT02029378
- Locations
- 🇬🇧
Southern General Hospital, Glasgow, United Kingdom
The De-novo Use of Eculizumab in Presensitized Patients Receiving Cardiac Transplantation
- First Posted Date
- 2013-12-17
- Last Posted Date
- 2021-05-03
- Lead Sponsor
- Cedars-Sinai Medical Center
- Target Recruit Count
- 36
- Registration Number
- NCT02013037
- Locations
- 🇺🇸
Cedars Sinai Medical Center, Heart Institute, Los Angeles, California, United States
Eculizumab for Prevention of Delayed Graft Function (DGF) in Kidney Transplantation
- Conditions
- Interventions
- First Posted Date
- 2013-08-09
- Last Posted Date
- 2018-02-27
- Lead Sponsor
- Heeger, Peter, M.D.
- Target Recruit Count
- 21
- Registration Number
- NCT01919346
- Locations
- 🇺🇸
Yale - New Haven Hospital, New Haven, Connecticut, United States
🇺🇸Icahn School of Medicine at Mount Sinai, New York, New York, United States
🇺🇸University Hospitals Case Medical Center, Cleveland, Ohio, United States
Efficacy and Safety of Eculizumab for Treatment of Antibody-mediated Rejection Following Renal Transplantation
- Conditions
- Interventions
- First Posted Date
- 2013-07-10
- Last Posted Date
- 2017-09-21
- Lead Sponsor
- Brigham and Women's Hospital
- Target Recruit Count
- 11
- Registration Number
- NCT01895127
- Locations
- 🇺🇸
UCSF Medical Center, San Francisco, California, United States
🇺🇸Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸University of Michigan Medical Center, Ann Arbor, Michigan, United States
A Randomized Controlled Trial of Eculizumab in AQP4 Antibody-positive Participants With NMO (PREVENT Study)
- Conditions
- Interventions
- First Posted Date
- 2013-07-04
- Last Posted Date
- 2019-06-26
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 143
- Registration Number
- NCT01892345
- Locations
- 🇺🇸
John Hopkins University School of Medicine, Baltimore, Maryland, United States
🇦🇺University of Sydney, Brain and Mind Center, Camperdown, New South Wales, Australia
🇦🇺St. Vincent's Hospital Melbourne, Fitzroy, Victoria, Australia
The Safety and Efficacy of Eculizumab in Japanese Patients With Atypical Hemolytic Uremic Syndrome (aHUS)
- First Posted Date
- 2012-12-31
- Last Posted Date
- 2017-03-10
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 2
- Registration Number
- NCT01757431
- Locations
- 🇯🇵
Nagano Red Cross Hospital, Nagano, Japan
🇯🇵Tokyo Medical and Dental University Hospital, Tokyo, Japan
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.